Cannabidiol is currently a class B1 controlled drug in New Zealand under the Misuse of Drugs Act. It is also a prescription medicine under the Medicines Act. In 2017 the rules were changed so that anyone wanting to use it could go to the Health Ministry for approval. Prior to this, the only way to obtain a prescription was to seek the personal approval of the Minister of Health.
CBD, or canabidiol is an amazingly useful plant compound that is extracted from the cannabis plant. With volumes of medical science now at its back, this compound has been used effectively for a wide range of needs. These particularly wide-ranging applications are the result of its being a part of the “pleiotropic sedate” group. Compounds in this group are especially unique in their ability to affect and travel along many of the typically closed atomic pathways.
Other “minor phytocannabinoids” in cannabis may also contribute relevant activity (McPartland and Russo 2001). Cannabichromene (CBC) is the third most prevalent cannabinoid in cannabis, and is also anti-inflammatory (Wirth et al 1980), and analgesic, if weaker than THC (Davis and Hatoum 1983). Cannabigerol (CBG) displays sub-micromolar affinity for CB1 and CB2 (Gauson et al 2007). It also exhibits GABA uptake inhibition to a greater extent than THC or CBD (Banerjee et al 1975), suggesting possible utilization as a muscle relaxant in spasticity. Furthermore, CBG has more potent analgesic, anti-erythema and lipooxygenase blocking activity than THC (Evans 1991), mechanisms that merit further investigation. It requires emphasis that drug stains of North American (ElSohly et al 2000; Mehmedic et al 2005), and European (King et al 2005) cannabis display relatively high concentrations of THC, but are virtually lacking in CBD or other phytocannabinoid content.
Chronic pain: The body’s ECS plays a role in alleviating and managing pain, so CBD oil can work as a supplement for individuals with medical conditions that cause chronic pain, such as arthritis and multiple sclerosis. CBD oil also increases levels of adenosine in the brain; adenosine is a neurotransmitter that aids cardiovascular function and eases painful inflammation.
While these CDB laws are well intentioned and make certain types of cannabis oil legal in certain states, many of them are extremely exclusive as to what illnesses may qualify patients for use, and limit production of the plant—in most cases Charlotte's Web— to a handful of licensed facilities. These laws have drawn both praise and criticism from various groups, as many feel they stop well short of where we eventually need to be in regards to Medical Marijuana Oil and Medical Cannabis, limiting the use to only a handful of patients that are on a very short list of approved conditions and in some cases, exclusively for Epilepsy.
Cannabis was criminalized in various countries beginning in the 19th century. The British colonies of Mauritius banned cannabis in 1840 over concerns on its effect on Indian indentured workers; the same occurred in British Singapore in 1870. In the United States, the first restrictions on sale of cannabis came in 1906 (in District of Columbia). It was outlawed in Jamaica (then a British colony) in 1913, in South Africa in 1922, and in the United Kingdom and New Zealand in the 1920s. Canada criminalized cannabis in The Opium and Narcotic Drug Act, 1923, before any reports of the use of the drug in Canada, but eventually legalized its consumption for recreational and medicinal purposes in 2018.
Armentano pointed to several pieces of evidence as proof that CBD has always been treated as illegal at the federal level. Congress has tried and is currently trying to pass bills to remove CBD from the Controlled Substances Act—which would be unnecessary if the compound were already legal. Further, the Controlled Substances Act itself specifies that the government has the right to control substances that are chemically similar to the ones explicitly listed.
The anti-inflammatory contributions of THC are also extensive, including inhibition of PGE-2 synthesis (Burstein et al 1973), decreased platelet aggregation (Schaefer et al 1979), and stimulation of lipooxygenase (Fimiani et al 1999). THC has twenty times the anti-inflammatory potency of aspirin and twice that of hydrocortisone (Evans 1991), but in contrast to all nonsteroidal anti-inflammatory drugs (NSAIDs), demonstrates no cyclo-oxygenase (COX) inhibition at physiological concentrations (Stott et al 2005a).
Our products include foods that are prepared in a way that safeguards their nutritional value. The majority of these ingredients are grown locally on our certified organic farm and may require chopping, dicing, juicing and/or drying for use in our products. The resulting whole food ingredients are then added to a formula that may include whole food extracts, animal tissue extracts and concentrates, botanicals, whole food isolates and synthetic ingredients. These highly complex combinations contain a variety of elements designed to trigger trophic effects that support the body’s healthy balance and wellness.*
A. When a product is in violation of the FD&C Act, FDA considers many factors in deciding whether or not to initiate an enforcement action. Those factors include, among other things, agency resources and the threat to the public health. FDA also may consult with its federal and state partners in making decisions about whether to initiate a federal enforcement action.
As we continue to work with CBD our knowledge of the power of this plant is growing as well. We are obtaining much better results as we work with our patients to think themselves out of pain. You might think I’m kidding, but I’m not. Chronic pain changes the brain and lays down dysfunctional pathways. CBD promotes neuroplasticity and neurogenesis – the formation of new brain cells that develop into new pathways of thinking. We are encouraged and excited to continue to work with CBD to maximize its potential to address chronic pain.
There are also other difficulties in researching the effects of cannabis. Many people who smoke cannabis also smoke tobacco. This causes confounding factors, where questions arise as to whether the tobacco, the cannabis, or both that have caused a cancer. Another difficulty researchers have is in recruiting people who smoke cannabis into studies. Because cannabis is an illegal drug in many countries, people may be reluctant to take part in research, and if they do agree to take part, they may not say how much cannabis they actually smoke.
In recent years however, with increasing state legalization of cannabis and a burgeoning multibillion-dollar cannabis industry, US farmers have increasingly lobbied to remove federal restrictions against growing hemp. The Agricultural Act of 2014 (aka the 2014 Farm Bill) signed by President Obama set the stage for this to happen by loosened restrictions on hemp, allowing universities and state agriculture departments to grow it for research purposes. Now the 2018 Farm Bill opens those gates more broadly, allowing licensed farmers to grow hemp and transport it across state lines based on agreements and regulations to be established between states and the federal government.
Though unflavored and priced higher than competitors, Green Roads CBD oils are made by a trusted manufacturer and use organically grown hemp. Following the CO2 supercritical fluid extraction process, board-certified pharmacists formulate the tincture by hand. Green Roads only sells CBD isolates, so if you’re looking for broad-spectrum products look to some of our other recommendations.
In a Phase II double-blind, randomized, placebo-controlled, 5-week study of 56 rheumatoid arthritis patients with Sativex (Blake et al 2006), employed nocturnal treatment only to a maximum of 6 sprays per evening (16.2 mg THC + 15 mg CBD). In the final treatment week, morning pain on movement, morning pain at rest, DAS-28 measure of disease activity, and SF-MPQ pain at present all favored Sativex over placebo (Table 1).
CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere. A 2010 brain cancer study by California scientists found that CBD “enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival.” This means that CBD makes THC even more potent as an anticancer substance. Also in 2010, German researchers reported that CBD stimulates neurogenesis, the growth of new brain cells, in adult mammals.
Some CBD oil brands can be evasive when it comes to product testing details. Populum addresses this by including a hard copy of the oil’s lab testing results in the product packaging. Full lab results are easily accessible on the brand’s website, as well. Prices for the Populum CBD oil range from 18 to 24 cents per milligram, depending on the container size, making it a relatively inexpensive full spectrum product. All U.S. military veterans receive a 25% discount, as well. Populum offers a risk-free 30-night product trial.
One of the main benefits of using CBD for pain relief is the fact that it doesn’t cause the same dependency that people get from using pharmaceutical pain medication. People have been looking into alternative pain medication for a long time – in fact plant-based treatments such as turmeric and frankincense have been used for a long time as natural therapies for pain. Cannabidiol is one such treatment that has a long history as a pain medication. Only recently the medical sector has acknowledged its use as a legitimate treatment for a variety of ailments including chronic pain.
“We continue to estimate a $250-500B potential long-term global cannabis market, with a $15-50B near-term opportunity,” analysts Michael Lavery and Jeffrey Kratky wrote in a note. “We expect intellectual property, value-added products, and form factor evolution to be key long-term drivers for the company.” Piper Jaffray rates the stock as overweight with a $60 price target, equal to 33% upside from its current trading level.
Most human studies of CBD have been done on people who have seizures, and the FDA recently approved the first CBD-based drug, Epidiolex, for rare forms of epilepsy. Clinical trials for other conditions are promising, but tiny. In one Brazilian study published in 2011 of people with generalized social anxiety disorder, for example, taking a 600-mg dose of CBD (higher than a typical dose from a tincture) lessened discomfort more than a placebo, but only a dozen people were given the pill.